Eris Lifesciences
BSE: 540596 | NSE: ERIS | ISIN: INE406M01024 | SECTOR: Biotechnology & DrugsOpen
943.00High
951.35Low
940.00Prev Close
940.85P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
127.86BVolume
3.84KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
-Ask
947.00
Promoter Pledge Holding - 6.01%
| Promoter Name | No of Shares | Percentage |
|---|---|---|
| Amit Indubhusan Bakshi | 81,76,470 | 6.01% |
Company Description
- Biotechnology & Drugs
BSE
540596NSE
ERISISIN
INE406M01024
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
Company Officers
Amit Bakshi
Chairman of the Board, Managing Director, Executive DirectorSachin Shah
Chief Financial OfficerKrishnakumar Vaidyanathan
Chief Operating Officer, Executive DirectorMilind Talegaonkar
Compliance Officer, Company SecretaryInderjeet Negi
Executive DirectorKaushal Shah
Executive Director